DUBLIN, June 24, 2015 /PRNewswire/ --
Research and Markets(http://www.researchandmarkets.com/research/p2jfpl/global_endocrine) has announced the addition of the "Global Endocrine Testing Market 2015-2019" report to their offering.
The global endocrine testing market to grow at a CAGR of 4.66% over the period 2014-2019.
Endocrine testing system refers to a collection of tests that involve all the glands of the body and the hormones produced by those glands. The endocrine system together with nervous system regulates and controls many internal body functions. While the endocrine system uses chemical messengers called hormones, the nervous system uses nerve impulses as a means of control. The endocrine system plays a role in reproduction, growth and sexual development, responses to injury and stress, body energy levels, bone and muscle strength, and internal balance of the body.
The global endocrine testing market is witnessing a shift from conventional (manual) to semi-automated and highly automated systems. Automation allows laboratories to increase productivity and efficiently handle higher test volumes with fewer people. It is also useful in cases of critical shortage of trained technicians. In addition, automated systems offer a level of precision that cannot be achieved consistently by manual methods. For instance, the adoption of AUF in endocrine testing is increasing. AUF involves preparation of a sample of therapeutic drugs (e.g. Dilantin) and hormones (e.g., testosterone) efficiently for various diagnostic procedures using an automated system. Thus, it can replace the existing manual centrifugation/dialysis preparation step. The current separation process involves dialysis, which takes about 18 hours, while with AUF technology, centrifugation can be done within 30 minutes.
According to the report, the number of people aged 60 and over will reach 2 billion people by 2050. By 2030, more than 22% of the world's population will be over 65. The elderly are more susceptible to diseases such as diabetes, hypertension, musculoskeletal and cardiovascular diseases, chronic kidney diseases, cerebral strokes, and cancer. Hence, the need for early and reliable diagnosis will boost the growth of the global endocrine testing market.
Further, the report states that limited detection and complexity of immunoassays will hinder the widespread adoption of endocrine testing devices and instruments.
To calculate the market size, we consider the revenue generated from the sales of the products (instruments and reagents) used in the following endocrine testing technologies:
Types of Diagnostic Technologies
- Clinical chemistry technologies
- Immunoassay technologies
- Tandem mass spectrometry
- Monoclonal and polyclonal antibodies
- Sensor technologies
- Others
The report also provides information about the following endocrine tests:
- FSH
- TSH
- hCG
- DHEAS
- Progesterone
- Testosterone
- Insulin
- Prolactin
- Cortisol
- Estradiol
- Luteinizing Hormone
Key Vendors
- Abbott Diagnostics
- Diascorin
- Roche Diagnostics
- Siemens Healthcare
- Thermo Fisher Scientific
Other Prominent Vendor
- AdnaGen
- Alere
- Allele Biotechnology
- Axis-Shield
- Beckman Coulter/Danaher
- Biomedical Diagnostics
- BioMerieux
- Bio-Rad
- Diametra
- Enzo Life Sciences
- Fujirebio
- ImmunoDX
- Immunonodiagnostics System
- InDevR
- Innogenetics
- Kyowa Medex
- Merck Millipore
- Meridian Bioscience
- Meso Scale Discovery
- NanoEnTek
- Nova Century Scientific
- Ortho-Clinical Diagnostics
- Quidel
- Randox
- SDIX
- Sysmex
- Tecan
- Tosoh Bioscience
- Vital Diagnostics
- ZEUS Scientific
For more information visit http://www.researchandmarkets.com/research/p2jfpl/global_endocrine
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
